Centers for Medicare & Medicaid Services granted coverage for NeoGenomics’ PanTracer LBx blood‑based comprehensive genomic profiling test for advanced solid tumors, potentially widening access to liquid biopsy–guided therapy selection and trial enrollment. CMS coverage signals growing payer recognition of circulating tumor DNA assays as clinically actionable in specific advanced‑disease contexts. NeoGenomics said the decision will support therapy selection workflows and clinical‑trial matching for patients with limited tissue options. Payers and providers will watch implementation closely to see how coverage terms and coding affect real‑world uptake and test utilization across oncology centers.